Evidence map›Paper›PMID 17673900›Full record

ArticleLeukemia2007

Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.

B N Savani, S Mielke, S Adams, M Uribe, K Rezvani, A S M Yong, J Zeilah, R Kurlander, R Srinivasan, R Childs and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

B N SavaniStem Cell Transplantation Section, Hematology Branch, National Institutes of Health, Bethesda, MD 20892-1202, USA.
S Mielke
S Adams
M Uribe
K Rezvani
A S M Yong
J Zeilah
R Kurlander
R Srinivasan
R Childs
N Hensel
A J Barrett
National Institutes of Health · USNational Institutes of Health Clinical Center · USNational Cancer Institute · US

Funding

Allogeneic Immunotherapy for cancer and nonmalignant hematological disordersZIAHL002345 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHILDS, RICHARD · 2009 to 2025
$53.3M
GRAFT-VERSUS-LEUKEMIAZ01HL002342 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI BARRETT, AUSTIN JOHN · 1994 to 2008
$7.7M
Allogeneic Immunotherapy for cancer and nonmalignant hematological disordersZ01HL002345 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHILDS, RICHARD · 2000 to 2008
$6.5M
Graft-versus-leukemiaZIAHL002342 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI BARRETT, AUSTIN JOHN · 2009 to 2010
$6.3M
Quantitating Engraftment Of Donor Hematopoietic Cells After TransplantationZ01CL010334 · CLC · CLINICAL CENTER · PI KURLANDER, ROGER J · 2002 to 2008
$46k
Quantitating Engraftment Of Donor Hematopoietic Cells After TransplantationZIDCL010334 · CLC · CLINICAL CENTER · PI KURLANDER, ROGER J · 2009 to 2015
$0k
6 · The paper itself

Abstract

Natural killer (NK) cells are the first lymphocytes to recover after allogeneic stem cell transplantation (SCT) and can exert powerful graft-versus-leukemia (GVL) effects determining transplant outcome. Conditions governing NK cell alloreactivity and the role of NK recovery in sibling SCT are not well defined. NK cells on day 30 post-transplant (NK30) were measured in 54 SCT recipients with leukemia and donor and recipient killer immunoglobulin-like receptor (KIR) genotype determined. In univariate analysis, donor KIR genes 2DL5A, 2DS1, 3DS1 (positive in 46%) and higher numbers of inhibitory donor KIR correlated with higher NK30 counts and were associated with improved transplant outcome. NK30 counts also correlated directly with the transplant CD34 cell dose and inversely with the CD3+ cell dose. In multivariate analysis, the NK30 emerged as the single independent determinant of transplant outcome. Patients with NK30 >150/microl had less relapse (HR 18.3, P=0.039), acute graft-versus-host disease (HR 3.2, P=0.03), non-relapse mortality (HR 10.7, P=0.028) and improved survival (HR 11.4, P=0.03). Results suggest that T cell-depleted SCT might be improved and the GVL effect enhanced by selecting donors with favorable KIR genotype, and by optimizing CD34 and CD3 doses.

Indexed as

AdolescentAdultAntigens, CD34CD3 ComplexChildCohort StudiesFemaleGenotypeGraft vs Leukemia EffectHLA AntigensHumansKiller Cells, NaturalLeukemia, MyeloidMaleMiddle AgedMonomeric GTP-Binding ProteinsAntigens, CD34CD3 ComplexGEM protein, humanHLA AntigensMonomeric GTP-Binding Proteins

Identifiers

PMID17673900
OpenAlexW2074094858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.